Episode
New covid vaccine for UK
- Podcast
- Dr. John Campbell
- Published
- Sep 10, 2026
- Duration seconds
- 1568
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/VG3436616729.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/dr-john-campbell-7851784/episodes/new-covid-vaccine-for-uk/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/dr-john-campbell-7851784/new-covid-vaccine-for-uk.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Bivalent new vaccine, Moderna press release https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx Omicron-containing bivalent COVID booster candidate, mRNA-1273.214 (original mRNA-1273 vaccine), Superior neutralizing antibody response in baseline seronegative participants. increased neutralizing geometric mean titers (GMT) against Omicron approximately 8-fold above baseline levels. mRNA-1273.214 50 μg booster dose, well-tolerated in the 437 study participants The safety and reactogenicity profile of the mRNA-1273.214 50 μg booster dose was similar to that of mRNA-1273 50 μg BA.1 SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 44 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1093275/covid-technical-briefing-44-22-july-2022.pdf BA.2 3.4% BA.4 17.2% BA.5 78.7% Other 0.7% US variants https://covid.cdc.gov/covid-data-tracker/#variant-proportions BA.5 88.8% BA.4 5.3% BA.4.6 5.1% BA.2.12.1 0.8% BA.2 0% BA.1s 0% Delta 0% Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793551 Population-based cohort study of 297 individuals in Ontario, Canada, with myocarditis or pericarditis following COVID-19 vaccination, found higher rates of myocarditis or pericarditis associated with receipt of mRNA-1273 compared with BNT162b2 as a second dose, particularly among male individuals aged 18 to 24 years. The results suggest that there may be product-specific differences…